Introduction Real-world data on the needs of patients with psoriasis and patient-perceived
benefits of apremilast are limited. We report such data from France. Methods The …

Abstract Introduction While several European studies have reported real-world apremilast
use, patient-perceived benefits, and treatment satisfaction, local reimbursement criteria for …

Introduction The broad and sustained efficacy of apremilast for psoriasis has been
demonstrated in randomized and real-world observational studies. Data from Central and …

Introduction In the real-world APPRECIATE study (NCT02740218), most patients with
psoriasis demonstrated notable improvements on disease severity measures and reported …

Background: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European
Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients …

Introduction Apremilast is approved for the treatment of psoriasis and psoriatic arthritis.
However, data on the efficacy and safety of apremilast in clinical practice are limited. We …

Introduction Psoriasis is a systemic inflammatory disease characterised by pruritic skin
lesions that impair quality of life (QOL). Long-Term Documentation of the Utilization of …

Introduction L'apremilast complète l'arsenal thérapeutique du psoriasis depuis octobre
2016. Les données des études cliniques sont rassurantes en termes de tolérance mais on …

Background and objectives It is necessary to expand the knowledge in the use of apremilast
in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the …

Background Real‐world data in patients with moderate psoriasis treated with apremilast is
limited. Objectives To evaluate the effectiveness and safety of apremilast in bio‐naïve …